Collaboration between the Immanuel Klinikum Bernau Herzzentrum Brandenburg, the Rheumazentrum Nord-Brandenburg and BioTeZ demonstrates new ways of treating rheumatoid arthritis. The results of the joint study are published in the current issue of the journal "Clinical and Experimental Rheumatology".
Through the introduction of therapeutic antibodies, the treatment results for rheumatoid arthritis (RA) have been significantly improved over the past decade. However, cases of inadequate effectiveness remain, as well as side effects due to the associated strong immunosuppression, especially with high activity levels. One possibility for therapy optimization is the targeted, individual dose adjustment of the active ingredients for each patient. At the moment, all RA patients treated with the TNF-alpha inhibitor adulimumab received a pre-approved standard dose of 40 mg every 14 days without regard for existing differences in body weight, sex, health status, metabolism and age. As a result, some patients receive too high drug dose and other patients have too low drug levels.
Using the test (recoveryEILSA from BioTeZ), it is now possible simultaneously quantify the concentrations of the therapeutic antibody adalimumab and the target antigen TNF alpha in the patient's serum during therapy (Zänker et al., 2017). The Figure 1 summarizes the results of the study, with the patients being divided into three groups.